|
|
||||||||||||||
|
|
|||||||||||||||
EPIDEMIOLOGY |
1 Department of Medicine, Pulmonary Division, University of Alberta, Edmonton, Alberta, Canada
2 The Institute of Health Economics, University of Alberta
Correspondence to:
Correspondence to:
Dr D D Sin, 2E4.29 Walter C Mackenzie Centre, University of Alberta, Edmonton, AB, Canada T6G 2B7;
don.sin{at}ualberta.ca
ABSTRACT
Background: Impaired lung function is a risk factor for cardiovascular morbidity. Whether circulating factors are responsible for this association is unknown. A study was undertaken to determine whether leptin, a hormone that can promote atherothrombosis, is raised in individuals with impaired lung function.
Methods: Data from non-obese participants in the Third National Health, Nutrition, and Examination Survey (n=2808) were analysed to determine the relationship between circulating leptin levels and forced expiratory volume in 1 second (FEV1) values divided into quintiles (quintile 1, FEV1 predicted
85.2%; quintile 2, 85.394.3%; quintile 3, 94.4101.4%; quintile 4, 101.5110.0%; and quintile 5,
110.1%).
Results: Serum leptin levels changed along the FEV1 gradient. The highest leptin levels were found in quintile 1 (geometric mean (GM) 5.42; interquartile range (IQR) 3.009.60 fg/l) and the lowest in quintile 5 (GM 4.94; IQR 2.809.10 fg/l). Adjustments for age, body mass index, and other confounders strengthened this relationship. Compared with quintile 5, the odds of having an increased serum leptin level in quintiles 1, 2, 3, and 4 were 2.26 (95% confidence interval (CI) 1.54 to 3.31), 2.20 (95% CI 1.52 to 3.17), 1.46 (95% CI 1.01 to 2.09), and 1.28 (95% CI 0.90 to 1.83), respectively.
Conclusion: Individuals with impaired lung function have raised serum leptin levels. Leptin may play a role in the pathogenesis of cardiovascular morbidity and mortality related to impaired lung function.
Keywords: leptin; lung function; epidemiology
Relevant Article
Thorax 2003 58: 647.
This article has been cited by other articles:
![]() |
J. A. Falk, O. A. Minai, and Z. Mosenifar Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Stolzmann, D. R. Gagnon, R. Brown, C. G. Tun, and E. Garshick Longitudinal Change in FEV1 and FVC in Chronic Spinal Cord Injury Am. J. Respir. Crit. Care Med., April 1, 2008; 177(7): 781 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Ochs-Balcom, B. J.B. Grant, P. Muti, C. T. Sempos, J. L. Freudenheim, M. Trevisan, P. A. Cassano, L. Iacoviello, and H. J. Schunemann Pulmonary function and abdominal adiposity in the general population. Chest, April 1, 2006; 129(4): 853 - 862. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. P. Man and D. D. Sin Effects of Corticosteroids on Systemic Inflammation in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 78 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Varraso, V. Siroux, J. Maccario, I. Pin, F. Kauffmann, and on behalf of the Epidemiological Study on the Gene Asthma Severity Is Associated with Body Mass Index and Early Menarche in Women Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 334 - 339. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |